» Articles » PMID: 19688103

Is Thrombophilia a Major Risk Factor for Deep Vein Thrombosis of the Lower Extremities Among Lebanese Patients?

Overview
Publisher Dove Medical Press
Date 2009 Aug 19
PMID 19688103
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Factor V Leiden (R506Q) mutation is the most commonly observed inherited genetic abnormality related to vein thrombosis. Lebanon has one of the highest frequencies of this mutation in the world with a prevalence of 14.4% in the general population. The aim of this study is to define risk factors including inherited genetic abnormalities among Lebanese patients with lower extremity deep vein thrombosis. We report the clinical outcome of patients with thrombophilia.

Methods: From January 1998 to January 2008, 162 patients (61 males and 101 females) were diagnosed with lower extremity deep vein thrombosis. Mean age was 61 years (range: 21 to 95 years).

Results: The most frequent risk factors for vein thrombosis were surgery, advanced age, obesity, and cancer. Twenty-five patients had thrombophilia, 16 patients had factor V Leiden (R506Q) mutation, and seven patients had MTHFR C677T mutation. Ninety-two percent of patients screened for thrombophilia were positive. Screening was requested in young patients (16), patients with recurrent (11), spontaneous (8), and extensive (5) venous thrombosis, familial history (5), pregnancy (4), estroprogestative treatment (3), and air travel (1). Nine patients had one, 11 patients had two, and five had three of these conditions. Follow-up (6 to 120 months) of these 25 patients treated with antivitamin K did not reveal recurrences or complications related to venous thromboembolism.

Conclusion: Factor V Leiden mutation followed by MTHFR mutation are the most commonly observed genetic abnormalities in these series. Defining risk factors and screening for thrombophilia when indicated reduce recurrence rate and complications. Recommendations for thrombophilia screening will be proposed.

Citing Articles

Rare case of simultaneous cerebral artery and venous sinus thrombosis in the setting of elevated factor VIII and combined oral contraceptive pills.

Safan A, Hamid O, Al-Mashdali A, AlSaud A, Al-Shokri S, Hamad A Clin Case Rep. 2022; 10(3):e05560.

PMID: 35317061 PMC: 8922538. DOI: 10.1002/ccr3.5560.


Should we screen Eastern Mediterranean COVID-19 patients for inherited thrombophilia?.

El Hasbani G, Taher A Med Hypotheses. 2021; 152:110621.

PMID: 34116360 PMC: 8176888. DOI: 10.1016/j.mehy.2021.110621.


Three-factorial Genetic Thrombophilia with Recurrent Thrombotic Events in a Saudi Patient: A Case Report.

Al Sultan O, Al Ibrahim E Saudi J Med Med Sci. 2020; 8(3):217-222.

PMID: 32952515 PMC: 7485664. DOI: 10.4103/sjmms.sjmms_231_18.


High prevalence of protein C, protein S, antithrombin deficiency, and Factor V Leiden mutation as a cause of hereditary thrombophilia in patients of venous thromboembolism and cerebrovascular accident.

Ali N, Ayyub M, Khan S Pak J Med Sci. 2015; 30(6):1323-6.

PMID: 25674132 PMC: 4320724. DOI: 10.12669/pjms.306.5878.


Influence of acquired and genetic risk factors on the prevention, management, and treatment of thromboembolic disease.

Kreidy R Int J Vasc Med. 2014; 2014:859726.

PMID: 25057415 PMC: 4099036. DOI: 10.1155/2014/859726.


References
1.
Seligsohn U, Lubetsky A . Genetic susceptibility to venous thrombosis. N Engl J Med. 2001; 344(16):1222-31. DOI: 10.1056/NEJM200104193441607. View

2.
Rosendaal F . Venous thrombosis: a multicausal disease. Lancet. 1999; 353(9159):1167-73. DOI: 10.1016/s0140-6736(98)10266-0. View

3.
Yun S, Kim J, Kim K, Sung G, Lee D, Kim J . Deep venous thrombosis caused by congenital absence of inferior vena cava, combined with hyperhomocysteinemia. Ann Vasc Surg. 2004; 18(1):124-9. DOI: 10.1007/s10016-003-0087-x. View

4.
Rees D, Cox M, Clegg J . World distribution of factor V Leiden. Lancet. 1995; 346(8983):1133-4. DOI: 10.1016/s0140-6736(95)91803-5. View

5.
Heit J, Silverstein M, Mohr D, Petterson T, OFallon W, Melton 3rd L . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160(6):809-15. DOI: 10.1001/archinte.160.6.809. View